Sangamo Biosciences (SGMO) Misses Q3 EPS by 2c

Sangamo Biosciences (NASDAQ: SGMO) reported Q3 EPS of ($0.27), $0.02 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $4.24 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.

You May Also Be Interested In

• AI and memory not a classic bubble, but future returns uncertain - strategist
• SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
• Citi raises Okta price target to $205, keeps Neutral rating